Phio Pharmaceuticals Corp. — Form 8-K Summary
Filing date and event: September 28, 2026. The filing reports results of the company’s 2026 Annual Meeting of Stockholders, held by live webcast. It does not report quarterly or annual operating results.
Business and financial context
The filing contains no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics, and provides no financial guidance or outlook.
Annual meeting actions
- Stockholders elected all six director nominees to serve until the 2027 Annual Meeting.
- Stockholders ratified Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026: 5,087,608 votes for, 88,779 against, and 31,193 abstentions.
- Stockholders approved an amendment to the 2020 Long Term Incentive Plan, effective upon approval, adding 1,500,000 shares to the plan’s available issuance pool. The total available for issuance is now 2,452,017 shares.
Voting and potential dilution
As of the August 4, 2026 record date, 11,617,250 common shares were issued and outstanding. A total of 5,207,580 shares were present or represented by proxy at the meeting. The plan amendment received 1,155,945 votes for, 194,070 against, and 34,468 abstentions; 3,823,097 broker non-votes were reported. The increased share pool creates potential dilution if shares are issued under the plan; the filing does not state how many shares, if any, have been granted or will be issued.
Other matters and investor checks
- The filing reports no director departures, officer appointments, or other unusual items beyond the plan amendment and annual-meeting results.
- Verify the plan amendment’s terms in Exhibit 10.1 and the detailed proposal description in the 2026 proxy statement filed August 14, 2026.
- Review subsequent filings for actual awards or share issuances under the expanded plan and their dilution impact.